Imagine CRISPR cures
By Fyodor D. Urnov,
Molecular Therapy
| 10. 27. 2021
A decade of progress in sequencing and in CRISPR/Cas technologies has created a situation without precedent in the history of medicine. Starting with an individual patient, next-generation sequencing can diagnose, in less than 24 h, the genetic basis of a Mendelian disorder.1 Once the causative mutation is found, CRISPR/Cas, in principle, represents a targeted therapy, a first-pass iteration of which can be designed in silico within minutes thanks to straightforward principles of target locus recognition by Cas9.2 The juxtaposition of the two to yield a treatment is not a hypothetical. For Mendelian disorders of hematopoiesis and those that can be treated by editing genes in the liver or the eye, a charted path exists to (1) engineer a CRISPR/Cas-based therapeutic, (2) complete IND-enabling preclinical safety, efficacy, and manufacturing studies, and (3) perform a phase 1/2 clinical trial. Three ongoing such trials have reduced all of this to practice,3,4 with a good safety record in ∼22 (sickle cell disease and transfusion-dependent β-thalassemia), 6 (TTR amyloidosis), and 6 (Leber's congenital amauropathy) subjects dosed to date; in the first case, all subjects for whom... see more
Related Articles
A Eugenics Society poster (1930s) from the
Wellcome Library Eugenics Society Archive via Wikimedia
On a Saturday afternoon in May, Payton S. Gendron shot 13 people, almost all Black, at a supermarket in Buffalo, killing 10. This was hardly an isolated incident: It was one of over 200 mass shootings so far this year. Only 10 days later, at least 21 people died in a school shooting at Uvalde, Texas. That killer was apparently a lonely, bullied 18-year-old with a...
By Michael Eisenstein , Nature | 05.09.2022
Two companies, Beam Therapeutics and Verve Therapeutics, are leading the charge of base editing therapies to the clinic. Last November, Beam got the green light from the US Food and Drug Administration (FDA) for its upcoming BEACON-101 trial that will...
By Kevin Davies, Genetic Engineering and Biotechnology News | 05.18.2022
WASHINGTON, DC — In his current role as President Biden’s acting scientific advisor, Francis Collins, MD, PhD, is dealing with a wide range of issues from semiconductor shortages to wildfires. “But my heart is in what you are all doing...
By Kathryn Paige Harden et al., The New York Review | 05.25.2022
In response to:
Why Biology Is Not Destiny from the April 21, 2022 issue
To the Editors:
Marcus Feldman and Jessica Riskin did not like my book. Or rather, they did not like a book called The Genetic Lottery...